- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Education and Support After Progression ALK Inhibitors
Panelists discuss how to approach patient education after progression on an ALK inhibitor, address real-world challenges during therapy transitions, and determine best options for patients progressing on lorlatinib.
EP: 1.The Evolution of ALK+ NSCLC Care
EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3
EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC
EP: 5.Key Differences Among ALK Inhibitors
EP: 6.Navigating ALK Inhibitor Toxicities
EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization
EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
EP: 11.Education and Support After Progression ALK Inhibitors
EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy
Patient Education and Transition Between Therapies
Key Themes:
- Approaches to patient education after disease progression
- Real-world challenges during therapy transitions
- Current options for patients progressing on lorlatinib
Notable Insights:
- Castronovo outlined approaches to patient education when discussing next steps after progression
- Grizzard identified real-world challenges patients face when transitioning between therapies
- Dr Dietrich presented current best options for patients progressing on lorlatinib
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
